TScan Therapeutics, Inc (TCRX) – Press Releases
-
TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
-
TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
-
TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
-
TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
-
TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
-
TScan Therapeutics Announces Closing of Upsized Public Offering
-
TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
-
TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
-
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
-
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer
-
TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference
-
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
-
TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR
-
TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR
-
TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development
-
TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer
-
TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR
-
TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress
-
TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition
-
TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations
-
TScan Therapeutics to Host Virtual KOL Event to Discuss Results from Ongoing Phase 1 Trial of TSC-100 and TSC-101 Presented at the 65th ASH Annual Meeting and Exposition
-
TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer
-
TScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive Years
-
TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-
TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting
-
TScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and Exposition
-
TScan Therapeutics Announces Upcoming Presentations at the 38th Society for Immunotherapy of Cancer Annual Meeting
-
Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors
-
TScan Therapeutics to Participate in Upcoming Investor Conferences
-
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME
-
TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-
TScan Therapeutics Announces Transition of Chief Financial Officer
-
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors
-
TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting
-
TScan Therapeutics Announces Closing of Public Offering
-
TScan Therapeutics to Participate in the Jefferies Healthcare Conference
-
TScan Therapeutics Announces Pricing of $140 Million Public Offering
-
TScan Therapeutics Announces Launch of Proposed Public Offering
-
TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors
-
TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting
-
TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting
-
TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease
-
AMGEN AND TSCAN THERAPEUTICS ANNOUNCE COLLABORATION TO IDENTIFY NOVEL TARGETS IN CROHN'S DISEASE
-
TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the American Society of Gene and Cell Therapy 26th Annual Meeting
-
TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the American Society of Gene and Cell Therapy 26th Annual Meeting
-
TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors
-
TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors
-
TScan Therapeutics Announces CEO Transition
Back to TCRX Stock Lookup
